TAM
CDTX

Tocqueville Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Tocqueville Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,150
Closed -$150K – 531
2024
Q1 		$150K Buy
8,150
+3,400
+72% +$48.8K ﹤0.01% 519
2023
Q4 		$75.4K Sell
4,750
-150
-3% -$2.41K ﹤0.01% 510
2023
Q3 		$92.3K Sell
4,900
-750
-13% -$14.7K ﹤0.01% 499
2023
Q2 		$128K Sell
5,650
-2,700
-32% -$63.5K ﹤0.01% 520
2023
Q1 		$212K Buy
8,350
+1,550
+23% +$44K ﹤0.01% 493
2022
Q4 		$103K Buy
6,800
+1,600
+31% +$19.1K ﹤0.01% 562
2022
Q3 		$65K Buy
+5,200
New +$71.8K ﹤0.01% 587

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Tocqueville Asset Management's CDTX Position: Q2 2024 in Review

Tocqueville Asset Management sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 8,150 shares — an estimated $150K sold.

Tocqueville Asset Management first reported a position in CDTX in Q3 2022 and held it in 7 quarters. The position peaked at $212K in Q1 2023. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Tocqueville Asset Management reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Tocqueville Asset Management sold 8,150 Cidara Therapeutics shares in Q2 2024, an estimated $150K.
  • Tocqueville Asset Management first reported a position in Cidara Therapeutics in Q3 2022 and held it in 7 quarters.
  • Tocqueville Asset Management's Cidara Therapeutics position peaked at $212K in Q1 2023.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Tocqueville Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.